Butane
CAS 106-97-8
Butane (CAS 106-97-8) is a Phase 1 pharmaceutical compound with 0 bioactivity targets and 32 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| BUTANE | 1310550 | SU | MTHSPL |
| Butane | 1310550 | SU | MTHSPL |
| butane | 1310550 | SU | MTHSPL |
| butane | 1310550 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Butane used for in pharmaceutical contexts?
Butane (CAS 106-97-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Butane?
Butane has 32 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Cardiac arrest, Cardio-respiratory arrest, Cerebral atrophy, Completed suicide, Drug abuse. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Butane also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Butane with EU status "restricted".
What clinical phase is Butane in?
Butane is rendered with ChEMBL max phase 1.